Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$507.55 USD

507.55
180,132

+1.21 (0.24%)

Updated Nov 4, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio

by Zacks Equity Research

IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.

    Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT

    by Zacks Equity Research

    Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.

      Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio

      by Zacks Equity Research

      A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.

        Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio

        by Zacks Equity Research

        Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.

          Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

          by Zacks Equity Research

          Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

            Integra Lifesciences Picked for Healogics iSupply Program

            by Zacks Equity Research

            Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.

              Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals

              by Zacks Equity Research

              Varian's (VAR) advanced cancer care solution prospects bright in the global market.

                Here's Why You Should Invest in Surmodics (SRDX) Stock Now

                by Zacks Equity Research

                Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.

                  IDEXX Gains Ground on Solid CAG Business Amid Forex Woes

                  by Zacks Equity Research

                  IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.

                    Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake

                    by Zacks Equity Research

                    Abbott (ABT) to see a rise in customer adoption of its DRG therapy following the receipt of new national coverage from Aetna.

                      Here's Why You Should Hold On to Quest Diagnostics (DGX) Now

                      by Zacks Equity Research

                      Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.

                        Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout

                        by Zacks Equity Research

                        Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.

                          Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit

                          by Zacks Equity Research

                          Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.

                            Genomic Health Prostate Cancer Business Solid, Cost Woes Stay

                            by Zacks Equity Research

                            Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.

                              Why Intuitive Surgical (ISRG) is a Top Pick for Momentum Investors

                              by Zacks Equity Research

                              Does Intuitive Surgical (ISRG) have what it takes to be a top stock pick for momentum investors? Let's find out.

                                Here's Why You Should Invest in athenahealth (ATHN) Now

                                by Zacks Equity Research

                                Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.

                                  Varian's (VAR) ProBeam System Gets Picked by Delray Medical

                                  by Zacks Equity Research

                                  Varian Medical's (VAR) coveted ProBeam platform sees a slew of developments; market prospects solid.

                                    HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates

                                    by Zacks Equity Research

                                    Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.

                                      Here's Why You Should Hold on to Abiomed (ABMD) for Now

                                      by Zacks Equity Research

                                      Abiomed's (ABMD) margin continues to remain pressed; an upbeat view for fiscal 2019 encourages.

                                        Amedisys Ties Up With Medalogix to Boost Home Health Unit

                                        by Zacks Equity Research

                                        Amedisys (AMED) pursues deals to boost Home Health business.

                                          Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3

                                          by Zacks Equity Research

                                          Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.

                                            Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

                                            by Zacks Equity Research

                                            Strong fundamentals and a solid Q2 aid Veeva (VEEV).

                                              Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

                                              by Zacks Equity Research

                                              Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

                                                Here's Why You Should Invest in Phibro (PAHC) Right Now

                                                by Zacks Equity Research

                                                Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.

                                                  Patterson Companies (PDCO) Misses Q1 Earnings Estimates

                                                  by Zacks Equity Research

                                                  Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.